MX2023007117A - Formulacion liquida para preparar un vehiculo de suministro que comprende un polimero termosensible y un polimero sensible a iones. - Google Patents

Formulacion liquida para preparar un vehiculo de suministro que comprende un polimero termosensible y un polimero sensible a iones.

Info

Publication number
MX2023007117A
MX2023007117A MX2023007117A MX2023007117A MX2023007117A MX 2023007117 A MX2023007117 A MX 2023007117A MX 2023007117 A MX2023007117 A MX 2023007117A MX 2023007117 A MX2023007117 A MX 2023007117A MX 2023007117 A MX2023007117 A MX 2023007117A
Authority
MX
Mexico
Prior art keywords
polymer
liquid delivery
delivery composition
composition
delivery vehicle
Prior art date
Application number
MX2023007117A
Other languages
English (en)
Inventor
Luigi Maria Longo
Cristina Macelloni
Silvia Rossi
Franca Ferrari
Cristina Bonferoni
Giuseppina Sandri
Original Assignee
Cosmo Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cosmo Technologies Ltd filed Critical Cosmo Technologies Ltd
Publication of MX2023007117A publication Critical patent/MX2023007117A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/006—Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0071—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form solution, solute
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Oncology (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona una composición para usarse como vehículo de suministro que comprende al menos un polímero termosensible (polímero A) y al menos un polímero sensible a iones (polímero B) en una formulación líquida. El polímero A es preferiblemente un copolímero en bloque de polioxietileno-polioxip ropileno o un derivado de celulosa. Polímero B un polisacárido. La composición puede incluir una sustancia activa para el suministro o puede usarse como un vehículo de suministro para una sustancia agregada en el momento de la administración, tal como células madre mesenquimales.
MX2023007117A 2017-12-22 2020-07-13 Formulacion liquida para preparar un vehiculo de suministro que comprende un polimero termosensible y un polimero sensible a iones. MX2023007117A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17210119.8A EP3501496A1 (en) 2017-12-22 2017-12-22 Liquid delivery composition

Publications (1)

Publication Number Publication Date
MX2023007117A true MX2023007117A (es) 2023-06-29

Family

ID=60782071

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020006664A MX2020006664A (es) 2017-12-22 2018-12-20 Composiciones liquidas de suministro.
MX2023007117A MX2023007117A (es) 2017-12-22 2020-07-13 Formulacion liquida para preparar un vehiculo de suministro que comprende un polimero termosensible y un polimero sensible a iones.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020006664A MX2020006664A (es) 2017-12-22 2018-12-20 Composiciones liquidas de suministro.

Country Status (10)

Country Link
US (2) US12011483B2 (es)
EP (2) EP3501496A1 (es)
JP (2) JP7494116B2 (es)
KR (2) KR20240133770A (es)
CN (1) CN111511352A (es)
BR (1) BR112020012519A2 (es)
CA (1) CA3081633A1 (es)
MX (2) MX2020006664A (es)
RU (1) RU2020124103A (es)
WO (1) WO2019122253A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4157998A4 (en) * 2020-06-02 2024-10-16 The Johns Hopkins Univ GEL FOR USE IN GASTROINTESTINAL ENDOSCOPY AND ENDODERMAL, EPIDERMAL AND OTHER MUCOSAIC APPLICATIONS
WO2023018649A1 (en) * 2021-08-10 2023-02-16 Bayer Healthcare Llc Liquid formulations comprising alginic acid, pectin, and carrageenan and methods of using thereof for gastric and gastroesophageal disorders
WO2023018661A1 (en) * 2021-08-10 2023-02-16 Bayer Healthcare Llc Liquid formulations comprising alginic acid, pectin, and carrageenan and methods of using thereof
EP4162928A1 (en) * 2021-10-05 2023-04-12 Cosmo Technologies Ltd. Rifamycin for the treatment of pouchitis, with an in-situ gelling formulation
JP2024536398A (ja) * 2021-10-05 2024-10-04 コスモ・テクノロジーズ・リミテツド 回腸嚢炎および遠位潰瘍性大腸炎を治療するためのリファマイシンのインサイチュゲル化浣腸剤

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5296236A (en) * 1988-09-16 1994-03-22 Recordati S.A., Chemical And Pharmaceutical Company Controlled release therapeutic system for a liquid pharmaceutical formulations
US5124151A (en) * 1990-08-07 1992-06-23 Mediventures Inc. Drug delivery by injection with thermo-irreversible gels
US5143731A (en) * 1990-08-07 1992-09-01 Mediventures Incorporated Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
US6280745B1 (en) * 1997-12-23 2001-08-28 Alliance Pharmaceutical Corp. Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions
KR100509119B1 (ko) 1999-07-16 2005-08-18 주식회사 엘지생활건강 프로시아니딘 올리고머를 유효성분으로 하는 약제
JP2006225398A (ja) 2002-04-01 2006-08-31 Kaken Pharmaceut Co Ltd 塩基性線維芽細胞増殖因子含有歯科用粘稠製剤
MXPA05010002A (es) * 2003-03-24 2006-03-10 Biosphere Medical Inc Embolizacion temporal utilizando polimeros termosensibles inversos.
CN101137370B (zh) * 2005-02-09 2014-08-13 参天制药株式会社 用于治疗疾病或病症的液体制剂
KR20100055482A (ko) 2007-08-16 2010-05-26 마커사이트, 인코포레이티드 안질환 또는 안이상의 치료를 위한 제제
WO2009090558A2 (en) * 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
KR101101321B1 (ko) 2008-11-03 2012-01-02 주식회사 엠씨티티 상처 치유를 위한 하이드로 겔 형태의 세포전달용 비히클 및 그 제조방법
WO2012135422A2 (en) 2011-04-01 2012-10-04 University Of Florida Research Foundation, Inc. Thermo-sensitive, mucoadhesive or dermoadhesive, and penetration-enhancing formulations for topical delivery of therapeutics
FR2994844B1 (fr) * 2012-08-31 2015-01-02 Assist Publ Hopitaux De Paris Formulation gelifiante a base de ketamine
CN107921033B (zh) 2015-04-08 2021-01-01 美治医药科技有限公司 供鼻内给药的格拉斯琼的生物粘着性组成物
MX2018001075A (es) 2015-07-28 2019-04-15 Vyome Therapeutics Ltd Agentes terapeuticos y profilacticos antibacterianos.
EP3173067B1 (en) 2015-11-16 2018-11-14 Istanbul Universitesi Rektorlugu Mucoadhesive buccal in situ gel formulation

Also Published As

Publication number Publication date
US20210154300A1 (en) 2021-05-27
US20240299551A1 (en) 2024-09-12
EP3727453A1 (en) 2020-10-28
MX2020006664A (es) 2020-08-31
KR20240133770A (ko) 2024-09-04
US12011483B2 (en) 2024-06-18
JP2024100934A (ja) 2024-07-26
BR112020012519A2 (pt) 2021-02-23
RU2020124103A (ru) 2022-01-24
EP3501496A1 (en) 2019-06-26
JP7494116B2 (ja) 2024-06-03
RU2020124103A3 (es) 2022-01-24
CN111511352A (zh) 2020-08-07
WO2019122253A1 (en) 2019-06-27
JP2021506913A (ja) 2021-02-22
KR20200103012A (ko) 2020-09-01
CA3081633A1 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
MX2023007117A (es) Formulacion liquida para preparar un vehiculo de suministro que comprende un polimero termosensible y un polimero sensible a iones.
CL2017001115A1 (es) Formulación estable de proteina en solución que contiene una alta concentración de un anticuerpo anti-vegf.
CL2019000586A1 (es) Composiciones de toxinas clostridiales no proteicas.
WO2018115097A9 (en) Ophthalmic composition for treatment of dry eye disease
IL279034A (en) Pharmaceutical combination, composition and formulation containing a glucokinase activator and an alpha-glucosidase inhibitor, preparation methods and uses thereof
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
GT201400285A (es) Formulacion de anticuerpos
WO2016004305A3 (en) Inhibitors of bruton's tyrosine kinase
EP3686184A3 (en) Ionizable compounds and compositions and uses thereof
BR112017009021A2 (pt) formulação farmacêutica de anticorpo anti-tnfa
MX2021001376A (es) Carboxamidas como inhibidores de proteasa específicos de ubiquitina.
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
MX2018016424A (es) Formulaciones de deposito.
CY1120488T1 (el) Υγρη φαρμακευτικη συνθεση
PH12019500949A1 (en) Ror-gamma modulators
WO2018141941A3 (en) Methods and systems for improving stability of pre-vapor formulations of e-vaping devices
MX2021007709A (es) Composiciones farmacéuticas oftálmicas y procedimientos para el tratamiento de las enfermedades de la superficie ocular.
PH12020550217A1 (en) Nutrient-spore formulations and uses thereof
CR20220355A (es) Compuestos activos frente a receptores nucleares
MX2022007265A (es) Compuestos activos frente a receptores nucleares.
MX2022006784A (es) Formulaciones de anticuerpos anti-pd-l1.
CL2020002766A1 (es) Formulaciones farmacéuticas mejoradas
MX2018014790A (es) Formulacion combinada de tres compuestos antivirales.
PH12018502139A1 (en) Phosphaplatin liquid formulations